French drugmaker Sanofi stamped its authority on newly bought Aventis on Tuesday by giving its own executives key board positions at its former rival, while it posted a better-than-expected 20 percent rise in first-half net profit.
French drugmaker Sanofi stamped its authority on newly bought Aventis on Tuesday by giving its own executives key board positions at its former rival, while it posted a better-than-expected 20 percent rise in first-half net profit.
